IP Library Granted Patent US 11,234,944
Granted Patent B2
US 11,234,944 · App. 17/075,586 · Granted Feb 1, 2022

Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof

Inventors: James Smeeding (Dallas, TX); Mathew Sherwood (Silverthorne, CO)
Assignee: Indication BioScience LLC
A61K31/05A61K9/006A61K31/22A61K31/352A61K31/366A61K31/405A61K31/47A61K31/505A61K36/185A61P9/10A61P21/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,234,944
App. No.
17/075,586
Granted
Feb 1, 2022
Kind
B2
Abstract

The invention relates to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis. It has been found that compositions combining a statin and a cannabinoid are improved over existing statin formulations. The compositions of the invention for example allow for a lower effective dose of statin and a reduction of the adverse effects seen with statins taken alone. Dosing ranges and formulations suitable for oral, buccal, and sublingual administration are disclosed. Various specific cannabinoids such as cannabidiol and synthetic cannabidiols selected for their anti-inflammatory, antioxidant, and anti-atherosclerotic effect are shown to be particularly advantageous.

Claims (16)

1. A pharmaceutical composition for once daily dosing, useful in treating a patient with a lipid disorder, comprising:

(a) a reduced daily dosage amount of a statin; and

(b) a cannabis extract;

wherein the reduced daily dosage amount of the statin is less than the standard daily dosage amount for the statin when taken alone, and wherein the pharmaceutical composition is formulated for oral or mucosal administration.

2. The pharmaceutical composition of claim 1 , wherein the statin is selected from the group consisting of: atorvastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.

3. The pharmaceutical composition of claim 1 , wherein the cannabis extract comprises between 1-500 mg of a cannabinoid.

4. The pharmaceutical composition of claim 3 , wherein the cannabinoid is CBD.

5. The pharmaceutical composition of claim 1 , wherein the cannabis extract is free of THC.

6. A method of treating a lipid disorder in a human in need of such treatment, the method comprising administering to the human a pharmaceutical composition for once daily dosing, comprising:

(c) a reduced daily dosage amount of a statin; and

(d) a cannabis extract;

wherein the reduced daily dosage amount of the statin is less than the standard daily dosage amount for the statin when taken alone, and wherein the pharmaceutical composition is formulated for oral or mucosal administration.

7. The method of claim 6 , wherein the statin is selected from the group consisting of: atorvastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.

8. The method of claim 6 , wherein the cannabis extract comprises between 1-500 mg of a cannabinoid.

9. The method of claim 8 , wherein the cannabinoid is CBD.

10. The method of claim 6 , wherein the cannabis extract is free of THC.

Assignments (2)
CERTIFICATE OF CONVERSION Recorded Mar 17, 2023
From: INDICATION BIOSCIENCE LLC
To: INDICATION BIOSCIENCE LLC
Reel/Frame 063116/0481 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: SHERWOOD, MATHEW D; SMEEDING, JAMES E
To: INDICATION BIOSCIENCE LLC
Reel/Frame 058466/0583 →
Continuity (3)
Continuation 16338663
Provisional Application 62403067 · Oct 1, 2016
Related Publication 20210030697A1 · Feb 4, 2021